Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Trevi Therapeutics, Inc. - Common Stock
(NQ:
TRVI
)
12.08
-0.21 (-1.71%)
Delayed Quote
Updated: 3:01 PM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Trevi Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Trevi Therapeutics Q2 Earnings Call Highlights
↗
August 07, 2026
Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,...
Via
MarketBeat
Topics
Earnings
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
↗
June 03, 2026
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
↗
May 09, 2026
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming...
Via
MarketBeat
Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Program
↗
March 17, 2026
Via
Chartmill
Earnings Scheduled For November 13, 2025
↗
November 13, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Earnings Preview For Trevi Therapeutics
↗
May 07, 2025
Via
Benzinga
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
↗
March 23, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Via
The Motley Fool
Trevi Therapeutics (TRVI) Earnings Transcript
↗
March 18, 2026
Trevi Therapeutics (TRVI) Earnings Transcript
Via
The Motley Fool
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns
↗
March 09, 2026
The company announced its decision following a meeting with the U.S. Food and Drug Administration.
Via
Stocktwits
MarketBeat’s Top 5 Rated Small-Cap Stocks
↗
December 22, 2025
Via
MarketBeat
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
↗
December 03, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash
↗
November 28, 2025
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via
The Motley Fool
Topics
Lawsuit
Regulatory Compliance
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash
↗
November 27, 2025
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via
The Motley Fool
Topics
Lawsuit
Regulatory Compliance
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
↗
November 27, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
↗
November 27, 2025
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Via
The Motley Fool
Topics
Regulatory Compliance
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans
↗
November 13, 2025
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
Via
Chartmill
A Peek at Trevi Therapeutics's Future Earnings
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 03, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
September 09, 2025
Via
Benzinga
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
August 21, 2025
Via
Benzinga
Dow Gains Over 100 Points; US Job Openings Increase In April
↗
June 03, 2025
Via
Benzinga
Topics
Stocks
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
↗
June 02, 2025
Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.
Via
Benzinga
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 18, 2025
↗
March 18, 2025
Via
Benzinga
Unusual volume stocks are being observed in Tuesday's session.
↗
March 11, 2025
In today's session, these stocks are experiencing unusual volume.
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 10, 2025
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
↗
March 10, 2025
Via
Benzinga
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
↗
March 10, 2025
Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
